Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
64.70
+0.85 (+1.33%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 7, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Gilead Sciences
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
Gilead Announces Clinical Trial Collaborations With Merck to Evaluate Trodelvy® in Combination With KEYTRUDA® in First-Line Metastatic Non-Small Cell Lung Cancer
January 10, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead's Rohini Mehtani, Ph.D. Reflects on The Importance of ASH21
January 04, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Russian Foundation Provides Career Guidance for Teens Living With HIV
December 28, 2021
SOURCE: Gilead Sciences
Via
3BL Media
Gilead Announces New England Journal of Medicine Publication of Data Demonstrating Veklury® (Remdesivir) Significantly Reduced Risk of Hospitalization in High-Risk Patients With COVID-19
December 22, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Commits to Electrifying Its Fleet
November 16, 2021
SOURCE: Gilead Sciences
Via
3BL Media
Gilead Sciences and Breast Cancer Awareness Month
December 22, 2021
SOURCE: Gilead Sciences
Via
3BL Media
Gilead Announces Clinical Hold on Studies Evaluating Injectable Lenacapavir for HIV Treatment and Prevention Due to Vial Quality Concerns
December 21, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead and Arcus Biosciences Complete Closing of Option Exercise for Three Clinical-Stage Programs and New Research Collaboration
December 21, 2021
From
Arcus Biosciences, Inc.
Via
Business Wire
Gilead Sciences to Present at Upcoming Investor Conference
December 21, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
The Global Breast Cancer Treatment Market Expected To Reach $34.06 Billion By End Of 2026
December 21, 2021
Palm Beach, FL – December 21, 2021 – FinancialNewsMedia.com News Commentary – Breast cancer is cancer that develops in the breast tissue. Breast cancer signs include the formation of a lump in the...
Via
FinancialNewsMedia
European Commission Expands Indication for Veklury (Remdesivir) for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression
December 21, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Daiichi Sankyo Authorizes the First YESCARTA® (Axicabtagene Ciloleucel) CAR T-cell Therapy Treatment Site in Japan
December 16, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Saying 'Not Today' to Triple-Negative Breast Cancer: Lee Ann's Journey
December 15, 2021
SOURCE: Gilead Sciences
Via
3BL Media
Yescarta® ZUMA-12 Study Demonstrates 78% Complete Response Rate as Part of First-Line Treatment in Newly Diagnosed High-Risk Large B-Cell Lymphoma
December 13, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Yescarta® Demonstrates Durable Two-Year Clinical Benefit in Adults With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Including Follicular Lymphoma
December 11, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Yescarta® Is First CAR T-cell Therapy to Report Five-Year Survival Data From Pivotal Study Showing Durable Long-Term Survival in Patients With Refractory Large B-cell Lymphoma
December 11, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Yescarta® CAR T-Cell Therapy Quadruples Median Event-Free Survival Duration Over Standard of Care in Second-Line Relapsed or Refractory Large B-Cell Lymphoma
December 11, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Trodelvy® Demonstrates Clinical Benefit for Black Patients Consistent with Full Metastatic Triple-Negative Breast Cancer Population in ASCENT Study
December 10, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
HIV Advisory Council in Australia Taps Diverse Community Perspectives
December 09, 2021
SOURCE: Gilead Sciences
Via
3BL Media
Exposures
COVID-19
Drug Combinations and New Approvals Delivering Optimistic Results in Oncology Stocks
December 08, 2021
FN Media Group Presents USA News Group News Commentary Vancouver, BC –December 8, 2021 – USA News Group – Growing at a healthy CAGR of 14.1%, the Cancer Immunotherapy Market is being projected to hit...
Via
FinancialNewsMedia
Gilead Sciences Ranked No. 6 overall, and No. 2 in Health Care & Life Sciences Industry, in Newsweek's List of Most Responsible American Companies
December 07, 2021
SOURCE: Gilead Sciences
Via
3BL Media
Gildead Sciences Is Proud to Be a Presenting Partner of National AIDS Memorial's World AIDS Day: December 1, 2021
December 01, 2021
SOURCE: Gilead Sciences
Via
3BL Media
Gilead Sciences Added to the Dow Jones Sustainability World Index
November 30, 2021
SOURCE: Gilead Sciences
Via
3BL Media
Topics
Stocks
Exposures
US Equities
Gilead’s Bold Ambition of Transforming Triple-Negative Breast Cancer Treatment to Be Highlighted With New Data at SABCS
November 29, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Trodelvy® (sacituzumab govitecan) Granted European Commission Marketing Authorization for Treatment of Metastatic Triple-Negative Breast Cancer in Second Line
November 23, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
The Importance of Self Advocacy in Breast Cancer: Janelle's Story
November 23, 2021
SOURCE: Gilead Sciences
Via
3BL Media
Topics
Product Recall
Exposures
Legal
Product Safety
Gilead Submits Biologics License Application to U.S. Food and Drug Administration for Bulevirtide, an Investigational Treatment for People Living With Chronic Hepatitis Delta
November 19, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences to Present at Upcoming Investor Conference
November 18, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Exercises Options to Three Arcus Biosciences Clinical-Stage Programs and Adds Research Collaboration
November 18, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
India's Efforts to Help End Hepatitis C Starts With Prison Population
November 18, 2021
SOURCE: Gilead Sciences
Via
3BL Media
Topics
Death
Exposures
COVID-19
Death
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.